By the end of this week, Moderna Therapeutics is likely to pull off the biggest initial public offering in biotech history, a $500 million fundraise with sweeping implications for the company, its innovative science, and the drug business as a whole.
Before Moderna — and its audacious plan to upend the industry — tests Wall Street’s appetite, here’s a guide to the outstanding questions pegged to biotech’s most scrutinized unicorn.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
As expected, Moderna stock falls from its IPO price on the first day of trading. https://news.alphastreet.com/moderna-nasdaq-mrna-stock-raises-over-600-million-through-ipo-to-debut-on-friday/